Feature|Articles|August 16, 2024

Pharmaceutical Executive

  • Pharmaceutical Executive: July/August 2024
  • Volume 44
  • Issue 7/8

Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.

Follow the links below to read about each product:

Exxua (Fabre-Kramer Pharmaceuticals)

Omvoh (Eli Lilly)

Truqap (AstraZeneca)

Wegovy (Novo Nordisk)

Winrevair (Merck & Co.)

Articles in this issue

over 1 year ago

Pharmaceutical Executive: July/August 2024 Issue (PDF)

over 1 year ago

An AI Pulse Check

over 1 year ago

A Promising Option: Exxua

over 1 year ago

Opening the Door: Omvoh

over 1 year ago

'Marked’ for Stardom?: Truqap

over 1 year ago

Branching Off: Wegovy

over 1 year ago

A Formidable First: Winrevair

over 1 year ago

The Future of Launch Excellence is Generative AI

over 1 year ago

From Potential to Value: Carving a Slice of the CGT ‘PIE'

over 1 year ago

Big Bets, Bold Steps

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content